RBC keeps USD 20 target for Xencor stock ahead of ESMO data

Published on 10/18/2026 at 13:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wells Fargo set a USD 30 target on October 15, 2026. Xencor stock last stood at USD 22.85 on Nasdaq on October 16, 2026 versus that target.

Analyst signals and clinical dates

RBC Capital maintained a USD 20.00 target and Buy rating on October 16, 2026.
Wells Fargo set a USD 30.00 target on October 15, 2026.
Xencor stock was last at USD 22.85 on Nasdaq on October 16, 2026.
The XmAb819 presentation is scheduled for October 23-27, 2026.

XNCR, US98401F1057, Illustration mit AI erstellt.

Xencor stock (ISIN US98401F1057) is tied to a USD 20.00 target after RBC Capital maintained its Buy rating on October 16, 2026, as Markets Insider reported. The near-term clinical event is an XmAb819 presentation scheduled for October 23-27, 2026, according to Investing.com.

Targets diverge across analysts

RBC Capital kept its USD 20.00 target and Buy rating in the report dated October 16, 2026. The same report cited a USD 32.00 consensus target, while the company was last quoted at USD 22.85 on Nasdaq on October 16, 2026 at 4:00 p.m. ET.

Wells Fargo initiated coverage with an Overweight rating and a USD 55.00 target on September 30, 2026, according to MarketBeat. A separate Wells Fargo report dated October 15, 2026 listed a USD 30.00 target, showing the range of published views rather than a single market consensus.

Three events changed the setup

The chronology began on August 5, 2026, when Xencor reported second-quarter revenue of USD 51.22 million and a GAAP loss of USD 0.29 per share; on September 28, 2026, MarketBeat reported Truist lifting its target from USD 27.00 to USD 29.00; on October 16, 2026, RBC maintained its USD 20.00 target and Buy rating, as MarketBeat and Markets Insider reported.

What does the clinical date mean?

The October presentation gives investors a defined point for assessing XmAb819, a Phase 1 bispecific antibody program focused on advanced clear cell renal cell carcinoma. The abstract was scheduled for October 18, 2026, while the presentation is set for October 23-27, 2026, in Madrid, Spain, according to Investing.com. Xencor says its XmAb platform supports antibody programs in cancer and autoimmune diseases, with partner development also contributing to the pipeline.

Revenue improved while losses continued

For the second quarter of 2026, revenue reached USD 51.22 million, up from USD 43.61 million in the second quarter of 2025, while the GAAP net loss narrowed to USD 21.73 million from USD 30.83 million, according to Markets Insider. The combination leaves the clinical readout as the next concrete test for the valuation debate.

Stock valuation and next catalyst

Xencor was last at USD 22.85 on Nasdaq on October 16, 2026 at 4:00 p.m. ET. The same market snapshot put its market capitalization at USD 1.7 billion and its 52-week range at USD 10.38 to USD 30.61.

The further course of trading is shown by the continuously updated real-time quote of Xencor stock.